Kenyan researchers find C. auris resistant to all four antifungal drug classes in a surgical patient

A culture result comes back from the lab, and someone has to decide what the ward does with it. In this case the hospital was told about the strain's resistance, in the authors' words, to "facilitate implementation of C. auris-specific infection prevention and control measures" ^[4]. The report does not detail what ultimately happened to the patient ^[5].

The headline over Gizmodo's coverage says the fungus "Keeps Learning How to Beat Every Drug We Throw at It" ^[7]. The evidence is narrower. It is one patient's strain, and the researchers say they cannot fully rule out that it came from the 2022 strain. They argue it more likely evolved pan-resistance on its own ^[10]. Gizmodo's own warning is conditional: if pan-resistance is happening regularly, one of these strains could eventually spread widely ^[14]. The researchers say this would be only the second documented case ^[8]. Two cases do not show regularity, so we would call "independent" a fair reading of the sequencing and "keeps learning" unproven.

The authors also say where the risk sits. They wrote that the strain's "resistance to four major antifungal classes highlights the escalating threat of untreatable fungal infections, particularly in settings with limited access to novel antifungal agents" ^[2]. For those hospitals, a four-class result may leave no further drug to try.

Gizmodo points to what still works. Outbreaks can be stopped with containment measures that do not involve antifungals ^[12]. Fully untreatable infections are likely to be especially rare ^[11]. Scientists are also working on other interventions, such as vaccines ^[13].

The audience for all of this is the infection-prevention lead at a hospital that does elective surgery, and the lab director who feeds that person. Two tests sort the situation. One is whether each C. auris isolate gets tested against all four classes. The other is whether a resistant result starts control measures on the ward without anyone having to ask for them. A result with no automatic trigger sits in a chart. A trigger with no result means containing blind.

We would wire the two together, so that a resistant result starts control measures on its own. The cost is that some patients will get those measures when their strain would have responded to drugs.